<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537444</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-ST-208</org_study_id>
    <nct_id>NCT02537444</nct_id>
  </id_info>
  <brief_title>Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)</brief_title>
  <official_title>A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerta Pharma BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Acerta Pharma BV</source>
  <brief_summary>
    <textblock>
      To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and
      acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian
      cancer
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The overall response rate (ORR) of acalabrutinib monotherapy and in combination with pembrolizumab in patients with recurrent ovarian cancer</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: acalabrutinib monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Combination of acalabrutinib and pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib</intervention_name>
    <arm_group_label>Regimen 1</arm_group_label>
    <other_name>ACP-196</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acalabrutinib and pembrolizumab combination</intervention_name>
    <arm_group_label>Regimen 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ≥ 18 years of age.

          -  Histologically confirmed ovarian epithelial (including fallopian tube and primary
             peritoneal) carcinoma.

          -  Progression of disease after the most recent anticancer treatment. At least 1 prior
             chemotherapy regimen must have included a taxane.

          -  Platinum-sensitive ovarian cancer defined by recurrence or progression of disease &gt; 6
             AND &lt; 24 months after completion of the most recent platinum-based therapy.

          -  Measurable disease as defined by RECIST 1.1.

          -  ECOG performance status of 0 or 1.

          -  Completion of all therapy for the treatment of cancer 2 weeks before the start of
             study therapy and recovered.

        Exclusion Criteria:

          -  Evidence of platinum-refractory ovarian cancer defined as recurrence or progression
             during the first 6 cycles of or &lt; 6 months after the beginning of first-line platinum
             based chemotherapy.

          -  Evidence of platinum-resistant ovarian cancer defined as recurrence or progression
             within 6 months after completing the most recent platinum-based therapy.

          -  More than 3 prior lines of cytotoxic chemotherapy for ovarian cancer.

          -  Prior malignancy (other than ovarian cancer), except for adequately treated basal cell
             or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the
             subject has been disease free for ≥ 2 years or which will not limit survival to &lt; 2
             years.

          -  Breastfeeding and pregnant.

          -  Known central nervous system metastases and/or carcinomatous meningitis.

          -  Subjects with active cardiovascular disease not medically controlled or those who have
             had myocardial infarction in the past 6 months..

          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel, symptomatic inflammatory bowel disease,
             partial or complete bowel obstruction.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ramies, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acerta Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Gynecology Oncology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordan Center For Gynecologic Cancer At Penn</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

